Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects

Journal of Cardiovascular Pharmacology

Volumn 54, Issue 3, 2009, Pages 196-203

  Roth, Eli M ^a   Bays, Harold E ^b   Forker, Alan D ^c   Maki, Kevin C ^d   Carter, Roderick ^e   Doyle, Ralph T ^e   Stein, Evan A ^f  

^a UNIVERSITY OF CINCINNATI   (United States)

^b LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^c UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^d Provident Clinical Research   (United States)

^e GLAXOSMITHKLINE   (United Kingdom)

^f Metabolic and Atherosclerosis Research Center   (United States)

Author keywords

Apolipoprotein; Atherogenic dyslipidemia; Fibrates; Omega 3 fatty acids; Triglycerides

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; CREATINE KINASE; FENOFIBRATE; FISH OIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; PLACEBO; REMNANTLIKE PARTICLE CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADJUVANT THERAPY; ADULT; ANXIETY; ARTHRALGIA; ARTICLE; BACKACHE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; EVENING DOSAGE; FEMALE; FLATULENCE; GASTROENTERITIS; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INFLUENZA; INJURY; INSOMNIA; LACERATION; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORNING DOSAGE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SHOULDER PAIN; SIDE EFFECT; SINUSITIS; SKIN INJURY; SORE THROAT; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; ANTILIPEMIC AGENTS; BODY MASS INDEX; COMBINED MODALITY THERAPY; DIET RECORDS; DIET, FAT-RESTRICTED; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; MALE; MIDDLE AGED; PROCETOFEN; SEVERITY OF ILLNESS INDEX; TRIGLYCERIDES; YOUNG ADULT;

EID: 70349731956     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181b0cf71     Document Type: Article

References (25)

1. Ginsberg HN. New perspectives on atherogenesis: Role of abnormal triglyceride-rich lipoprotein metabolism. Circulation. 2002;106:2137-2142.
2. Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol. 1996;77:1179-1184. (Pubitemid 26186958)
3. Yadav D, Pitchumoni CS. Issues in hyperlipidemic pancreatitis. J Clin Gastroenterol. 2003;36:54-62.
4. Bays H. Rationale for prescription omega-3-acid ethyl ester therapy for hypertriglyceridemia: A primer for clinicians. Drugs Today (Barc). 2008; 44:205-246. (Pubitemid 351669107)
5. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
6. Chan DC, Watts GF, Barrett PH, et al. Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia. Diabetes. 2002; 51:2377-2386.
7. Bays HE, Tighe AP, Sadovsky R, et al. Prescription omega-3 fatty acids and their lipid effects: Physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc Ther. 2008;6:391-409.
8. Harris WS, Ginsberg HN, Arunakul N, et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk. 1997;4:385-391. (Pubitemid 28078682)
9. Pownall HJ, Brauchi D, Kilinc C, et al. Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis. 1999;143:285-297. (Pubitemid 29166909)
10. Goldberg AC, Schonfeld G, Feldman EB, et al. Fenofibrate for the treatment of type IV and V hyperlipoproteinemias: A double-blind, placebo-controlled multicenter US study. Clin Ther. 1989;11:69-83. (Pubitemid 19112878)
11. Antara® (fenofibrate) Capsules [package insert]. Waltham, Massachusetts: Oscient Pharmaceuticals; Sept. 2006.
12. Pejic RN, Lee DT. Hypertriglyceridemia. J Am Board Fam Med. 2006;19:310-316.
13. Bays H. Ezetimibe. Expert Opin Invest Drugs. 2002;11:1587-1604.
14. Davidson MH, Bays HE, Stein E, et al. Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects. Clin Cardiol. 2006;29:268-273. (Pubitemid 43865706)
15. GlaxoSmithKline, Inc. Clinical trial report: A pharmacokinetic interaction study evaluating the effect of Reliant Pharmaceuticals Inc. (Lovaza®) omega-3-acid ethyl esters capsules on the plasma pharmacokinetics of Reliant Pharmaceuticals Inc. (Antara™) fenofibrate capsules in healthy adult volunteers under fasting conditions. Available at: www.gsk-clinical studyregister.com/result-detail. jsp? protocolId = 111861&studyId = 24420& compound = Omega-3-Acid + Ethyl + Esters&type = Compound&letter range = All. Protocol ID 111861. Accessed May 15, 2009.
16. Maki KC, McKenney JM, Reeves MS, et al. Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia. Am J Cardiol. 2008;102:429-433.
17. McKenney JM, McCormick LS, Schaefer EJ, et al. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am J Cardiol. 2001;88:270-274.
18. Kastelein JJ, van der Steeg WA, Holme I, et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation. 2008;117:3002-3009.
19. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005; 352:1425-1435. (Pubitemid 40471450)
20. Pedersen TR, Faergeman O, Kastelein JJP, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL study: A randomized controlled trial. JAMA. 2005;294:2437-2445. (Pubitemid 41627921)
21. de Graaf J, van der Vleuten GM, ter Avest E, et al. High plasma level of remnant-like particles cholesterol in familial combined hyperlipidemia. J Clin Endocrinol Metab. 2007;92:1269-1275.
22. Davidson MH, Stein EA, Bays HE, et al. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: An 8-week, randomized, double-blind, placebo-controlled study. Clin Ther. 2007;29:1354-1367.
23. Barter P, Ginsberg HN. Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia. Am J Cardiol. 2008;102:1040-1045.
24. Nordoy A, Bonaa KH, Sandset PM, et al. Effect of omega-3 fatty acids and simvastatin on hemostatic risk factors and postprandial hyperlipemia in patients with combined hyperlipemia. Arterioscler Thromb Vasc Biol. 2000;20:259-265. (Pubitemid 30048373)
25. Chan DC, Watts GF, Mori TA, et al. Factorial study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral obesity. Eur J Clin Invest. 2002;32:429-436.